Michael Soileau, MD
Neurology · Georgetown, TXNPI 1922237817
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $845,983 of the $1,205,247 with a category attached, or 70.2%. 34 manufacturers reported payments, led by AbbVie at 47.8% of the total. Among neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,385 payments — averaging $505.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$576K
- Kyowa Kirin, Inc.$148K
- Biogen$119K
- Amneal Pharmaceuticals LLC$97K
- Teva Pharmaceuticals USA, Inc.$74K
- Acorda Therapeutics, Inc$39K
- plus $154K from 28 others
Across 188 payments — averaging $3601.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$415K
- Amneal Pharmaceuticals LLC$136K
- Abbott$43K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$42K
- Teva Pharmaceuticals USA, Inc.$41K
- Medtronic$435
What the payments were for
- Consulting fees$203,89817%
- Speaking & faculty fees$845,98370%
- Travel & lodging$109,5549%
- Food & beverage$39,7533%
- Education$6,0591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 636 | $575,870 |
| Kyowa Kirin, Inc. | 247 | $147,738 |
| Biogen | 137 | $118,503 |
| Amneal Pharmaceuticals LLC | 151 | $96,634 |
| Teva Pharmaceuticals USA, Inc. | 163 | $73,677 |
| Acorda Therapeutics, Inc | 72 | $38,510 |
| Neurocrine Biosciences, Inc. | 143 | $36,057 |
| Abbott | 173 | $35,027 |
| Merz Pharmaceuticals, LLC | 138 | $23,021 |
| Medtronic(2 entities) | 176 | $22,992 |
| MDD US Operations, LLC | 77 | $15,687 |
| Sunovion Pharmaceuticals Inc. | 44 | $15,139 |
| Lundbeck LLC | 11 | $1,934 |
| Acadia Pharmaceuticals Inc | 77 | $1,206 |
| Merz North America, Inc. | 23 | $984 |
| Ipsen Biopharmaceuticals, Inc | 18 | $372 |
| GE HealthCare | 12 | $229 |
| Insightec,inc | 9 | $227 |
| Arbor Pharmaceuticals, Inc. | 16 | $226 |
| Adamas Pharmaceuticals, Inc. | 14 | $224 |
| Boston Scientific | 8 | $213 |
| Azurity Pharmaceuticals, Inc. | 7 | $128 |
| Avanir Pharmaceuticals, Inc. | 7 | $114 |
| EMD Serono, Inc. | 1 | $90 |
| Avion Pharmaceuticals | 4 | $82 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Revance Therapeutics, Inc. | 3 | $70 |
| UCB, Inc. | 4 | $58 |
| Supernus Pharmaceuticals, Inc. | 2 | $43 |
| Vertical Pharmaceuticals, LLC | 3 | $35 |
| Eisai Inc. | 2 | $30 |
| Cala Health, Inc. | 1 | $19 |
| Corium, LLC | 1 | $19 |
| Saol Therapeutics Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Duopa$376,652
- NOURIANZ$142,921
- VYALEV$110,316
- Skyclarys$107,839
- INBRIJA$53,814
- RYTARY$45,042
- AUSTEDO$45,027
- Austedo XR$25,924
- BOTOX$25,570
- INGREZZA$23,335
- CREXONT$20,757
- INFINITY$20,282
- KYNMOBI$14,731
- ACTIVA$12,340
- Neuromodulation Dspsbls and Accs$12,000
- ONGENTYS$6,817
- Percept$5,600
- GOCOVRI$3,642
- XEOMIN$3,593
- NORTHERA$1,800
How this compares
$1,205,247 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 121 | $783,715 |
| RytaryCarbidopa/Levodopa | 360 | $637,560 |
| IngrezzaValbenazine Tosylate | 51 | $417,643 |
| NourianzIstradefylline | 80 | $247,186 |
| AustedoDeutetrabenazine | 14 | $207,049 |
| GocovriAmantadine Hcl | 73 | $162,329 |
| InbrijaLevodopa | 28 | $152,495 |
| Droxidopa | 25 | $81,801 |
| NuedextaDextromethorphan Hbr/Quinidine | 34 | $54,831 |
| XadagoSafinamide Mesylate | 24 | $41,188 |
| HorizantGabapentin Enacarbil | 17 | $27,369 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 189 | $23,484 |
| MyrbetriqMirabegron | 25 | $19,761 |
| BotoxOnabotulinumtoxina | 12 | $19,232 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 442 | $15,979 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $1,206 | $783,715121 claims |
| Amneal Pharmaceuticals LLCRytary | $96,634 | $637,560360 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $36,057 | $417,64351 claims |
| Kyowa Kirin, Inc.Nourianz | $147,738 | $247,18680 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $73,677 | $207,04914 claims |
| MDD US Operations, LLCGocovri | $15,687 | $162,32973 claims |
| Acorda Therapeutics, IncInbrija | $38,510 | $152,49528 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $114 | $54,83134 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $226 | $27,36917 claims |
| AbbVieBotox | $575,870 | $19,23212 claims |
| Merz North America, Inc.Xeomin | $984 | $14,26718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 neurology providers in Texas.
Other neurology in Georgetown
- Ann BassSan Antonio$1.7M
- William OndoHouston$1.4M
- Nirav PavasiaDallas$1.4M
- Mirla AvilaLubbock$1.3M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Benjamin GreenbergDallas$773K
- Annette OkaiPlano$730K
- Waleed El-FekyDallas$587K
- Sean MilliganAmarillo$580K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.